Highlights
Significant Risk Elevation
Patients with myocardial infarction (MI) caused by isolated coronary artery ectasia (CAE) have an 84% higher risk of the composite endpoint of all-cause death and recurrent MI compared to those with standard coronary anatomy.
High Incidence of Stent Thrombosis
Stent thrombosis occurred in 8.9% of the CAE group compared to only 1.5% in the control group, representing a nearly six-fold increase in this devastating complication.
Diffuse Involvement
The majority of isolated CAE cases presented as diffuse, multivessel disease, with over 71% classified as Markis Type I, indicating a systemic rather than localized vascular remodeling process.
Background: The Enigma of Coronary Artery Ectasia
Coronary artery ectasia (CAE) is characterized by a localized or diffuse dilation of the coronary artery lumen exceeding 1.5 times the diameter of the adjacent normal segment. While often observed in the presence of obstructive coronary artery disease (CAD), a small subset of patients presents with “isolated” CAE—dilation in the absence of significant atherosclerotic stenosis. Historically, CAE was often dismissed as an incidental angiographic finding or a variant of atherosclerosis. However, emerging evidence suggests that the unique hemodynamics within ectatic segments—characterized by blood flow stasis, turbulent flow, and delayed contrast washout—create a highly prothrombotic environment.
Despite these physiological insights, the long-term clinical prognosis of patients who experience an MI specifically due to isolated CAE has remained poorly defined. Clinicians often face a therapeutic dilemma: should these patients be treated with standard dual antiplatelet therapy (DAPT), or do they require more aggressive anticoagulation to mitigate the risks associated with stagnant flow? The study by Abaci et al. provides critical longitudinal data to address these uncertainties.
Study Design: Investigating Isolated Ectasia in MI
This retrospective cohort study included 404 patients who underwent coronary angiography and were diagnosed with their first MI caused by isolated CAE. To ensure the findings were specific to the ectatic pathology, the researchers applied strict exclusion criteria, removing any patients with more than 20% stenosis in any vessel other than the culprit lesion responsible for the index MI. This isolated CAE group was then compared against a control group of patients who experienced an MI but did not exhibit coronary ectasia.
Population and Classification
Of the total cohort, 63.9% of the index events were ST-elevation myocardial infarctions (STEMI). The researchers utilized the Markis Classification to categorize the extent of ectasia:
1. Markis I: Diffuse ectasia in two or three vessels (found in 71.3% of the CAE group).
2. Markis II: Diffuse ectasia in one vessel and localized ectasia in another (found in 26.7%).
3. Markis III: Diffuse ectasia in only one vessel.
4. Markis IV: Localized or segmental ectasia.
Endpoints
The primary outcome was a composite of all-cause mortality and nonfatal recurrent MI following the index hospitalization. Secondary outcomes included individual components of the primary endpoint and the incidence of stent thrombosis.
Key Findings: Elevated Risks and Stent Complications
The results of the study underscore a sobering reality for patients with isolated CAE. Over the follow-up period, the primary composite endpoint occurred in 26.7% of the isolated CAE group, significantly higher than the 16.3% observed in the control group (P=0.011).
Recurrent Events and Mortality
When dissecting the components of the primary endpoint, the difference was largely driven by recurrent MI. Recurrent infarction occurred in 22.8% of the CAE group versus 13.4% of the control group. Interestingly, although the rate of all-cause death was numerically higher in the CAE group (4.0% vs. 3.0%), this difference did not reach statistical significance in this specific cohort. After adjusting for multiple variables, the presence of CAE remained an independent predictor of adverse outcomes, with a Hazard Ratio (HR) of 1.84 for the composite endpoint and 2.07 for recurrent MI specifically.
The Challenge of Stent Thrombosis
Perhaps the most striking finding was the disparity in stent thrombosis rates. Patients with CAE who received stents during their index MI faced an 8.9% rate of stent thrombosis, compared to 1.5% in those without CAE (P<0.001). This suggests that the mechanical and rheological environment of an ectatic vessel may interfere with proper stent endothelialization or promote acute thrombus formation despite standard antiplatelet therapy.
Culprit Vessel Recurrence
The researchers also noted that recurrent MI in the CAE group frequently involved the same artery as the index infarct. This suggests that the ectatic segment remains a persistent nidus for thrombus formation even after the initial event is treated.
Expert Commentary: Mechanistic Insights and Clinical Implications
The findings from Abaci et al. challenge the traditional management of MI in the setting of ectasia. The high rate of recurrent MI and stent thrombosis suggests that the current standard of care—largely focused on atherosclerotic plaque stabilization—may be insufficient for the CAE phenotype.
Pathophysiological Considerations
The underlying mechanism for MI in isolated CAE is likely different from classic plaque rupture. Slow flow (TIMI frame count is often elevated in CAE) leads to increased shear stress and activation of the coagulation cascade. In the setting of PCI, the large diameter of the ectatic vessel makes accurate stent sizing difficult, often leading to malapposition, which is a well-known risk factor for stent thrombosis.
Therapeutic Dilemmas
Should we be using anticoagulation? While this study was not a randomized trial of therapy, the data suggests that antiplatelet therapy alone may not be enough to overcome the stasis-induced thrombotic risk. Some experts have suggested that the addition of a low-dose oral anticoagulant (similar to the COMPASS trial protocol) or even full anticoagulation might be necessary for patients with diffuse Markis Type I ectasia, though this must be balanced against bleeding risks.
Study Limitations
As a retrospective study, there is an inherent risk of selection bias. Furthermore, the study focused on isolated CAE, which represents a specific subset of the population. Whether these findings apply to patients with concomitant obstructive CAD and CAE remains a topic for further investigation. The study also does not provide granular data on the specific P2Y12 inhibitors used or the duration of DAPT, which could influence the stent thrombosis rates.
Conclusion: Moving Toward Tailored Management
The study by Abaci et al. confirms that isolated coronary artery ectasia is not a benign finding but rather a high-risk anatomical variant in the context of myocardial infarction. The doubling of recurrent MI rates and the nearly six-fold increase in stent thrombosis demand a higher level of clinical vigilance. For the clinician, these results suggest that patients with MI and isolated CAE require intensive follow-up and perhaps a more nuanced approach to antithrombotic therapy than their non-ectatic counterparts. Future prospective trials are urgently needed to determine if anticoagulation or specialized stenting techniques can mitigate the profound risks identified in this study.
References
1. Abaci A, Yerlikaya MG, Şahin T, et al. Long-Term Prognosis of Acute Myocardial Infarction Caused by Isolated Diffuse Coronary Artery Ectasia. Circ Cardiovasc Interv. 2026;19(2):e016071. doi:10.1161/CIRCINTERVENTIONS.125.016071.
2. Markis JE, Joffe CD, Cohn PF, et al. Clinical significance of coronary artery ectasia. Am J Cardiol. 1976;37(2):217-222.
3. Devabhaktuni V, Chakravarti S, Gupta R, et al. Coronary Artery Ectasia: A Review of Genetics, Pathology, Epidemiology, and Management. Clin Cardiol. 2016;39(12):749-755.
